

## CAC Oct. 19, 2021 – APPENDIX 4

For all the latest CNSC news, visit CNSC's homepage at <http://www.nuclearsafety.gc.ca/eng/>

---

**From:** cncs.info.ccsn@cncs-ccsn.gc.ca <cncs.info.ccsn@cncs-ccsn.gc.ca>  
**Sent:** Tuesday, November 9, 2021 3:31 PM  
**Subject:** Commission amends Ontario Power Generation's Darlington operating licence

The Commission has amended the Ontario Power Generation (OPG) power reactor operating licence, allowing the production of Molybdenum-99 (Mo-99) at the Darlington nuclear generating station. Mo-99 is used to produce a diagnostic imaging agent used in nuclear medicine.

The Commission made the decision following a public hearing in writing, which considered submissions from OPG, CNSC staff and 10 intervenors. OPG will work with BWXT Nuclear Energy Company and BWXT Canada Ltd. to install an isotope irradiation system at Darlington Unit 2 to produce Mo-99.

The Commission is satisfied that OPG has implemented programs for security, safeguards, and conventional health and safety to ensure the safe production of Mo-99.

Read the news release at <https://canada.ca/en/nuclear-safety-commission/news/2021/11/cncs-amends-ontario-power-generations-power-reactor-operating-licence-for-its-darlington-nuclear-generating-station-to-authorize-the-production-of-.html> for more information.

**From:** cncs.info.ccsn@cncs-ccsn.gc.ca <cncs.info.ccsn@cncs-ccsn.gc.ca>  
**Sent:** Monday, November 1, 2021 3:45 PM  
**Subject:** Commission issues decisions for Bruce Power and Canadian Light Source Inc.

The Commission recently issued 2 decisions.

Under an amendment to its licence, Bruce Power will now be able to produce Lutetium-177, a medical isotope used for cancer treatment, at the Bruce Nuclear Generating Station in Kincardine, Ontario. Following a public hearing in writing that heard submissions from Bruce Power, CNSC staff and 20 intervenors, the Commission has concluded that appropriate programs will be in place to safely carry out Lutetium-177 production activities under the amended licence.

For more details, visit <https://nuclearsafety.gc.ca/eng/the-commission/pdf/Decision-BrucePower-Lu-177-CMD21-H100-e.pdf>

The Commission has also approved a change to the licensing basis for the Canadian Light Source Inc. (CLSI) particle accelerator facility in Saskatoon, Saskatchewan. The amendment allows CLSI to test and develop electron sources so that electron source failures do not result in further extended outages.

Go to <https://nuclearsafety.gc.ca/eng/the-commission/pdf/Decision-CLSI-CMD21-H109-e.pdf> for more information.

**From:** CNSC.Info.CCSN@canada.ca <CNSC.Info.CCSN@canada.ca>  
**Sent:** Wednesday, October 27, 2021 12:47 PM  
**Subject:** Upcoming webinar series on regulatory framework and activities

Join us for a series of webinars to explain the regulatory framework, and CNSC's processes for licensing, certification and compliance verification. This is your opportunity to ask questions and speak with CNSC subject-matter experts.

Topics and dates:

- CNSC regulatory framework and role of regulatory documents – November 24, 2021
- How the CNSC conducts licensing activities – November 30, 2021
- How the CNSC conducts compliance and verification activities – December 8, 2021

We look forward to your participation.

For more information on these webinars and to register, visit <https://nuclearsafety.gc.ca/eng/stay-connected/get-involved/meet-the-nuclear-regulator/fall-regulatory-framework-and-activities.cfm>

**From:** CNSC.Info.CCSN@canada.ca <CNSC.Info.CCSN@canada.ca>  
**Sent:** Wednesday, October 20, 2021 11:55 AM  
**Subject:** Commission issues two decisions (Ontario Power Generation and BWXT Medical Inc.)

The Commission has issued two decisions:

The Ontario Power Generation (OPG) licence to prepare its site for the Darlington New Nuclear Project (DNNP) in Clarington, Ontario has been renewed for 10 years. The renewal allows OPG to continue preparations for the potential future construction and operation of a new nuclear generating station. If OPG decides to construct and operate the station, a separate application and licensing process, with public participation, will be required.

For more information on the DNNP decision, visit <https://canada.ca/en/nuclear-safety-commission/news/2021/10/cnsc-renews-ontario-power-generations-site-preparation-licence-for-its-darlington-new-nuclear-project.html>.

The Commission has issued a Class IB nuclear substance processing facility licence to BWXT Medical Ltd. to operate a nuclear medicine production facility in Ottawa, Ontario. The licence allows BWXT to process a variety of radioisotopes used in nuclear medicine.

This decision was made following a public hearing in June that heard submission from 21 intervenors, CNSC staff and BWXT.

For additional details, visit <https://canada.ca/en/nuclear-safety-commission/news/2021/10/cnsc-issues-bwxt-medical-ltd-a-class-ib-nuclear-substance-processing-facility-licence-to-operate-the-nuclear-medicine-production-facility.html>.

**From:** CNSC.Info.CCSN@canada.ca <CNSC.Info.CCSN@canada.ca>

**Sent:** Thursday, September 23, 2021 12:55 PM

**Subject:** Commission reaches a decision on pressure tubes

The Commission has confirmed or amended the orders issued to Bruce Power and Ontario Power Generation concerning elevated levels of hydrogen equivalent (Heq) in pressure tubes.

Also, no unit can restart without Commission approval and specific qualitative and quantitative data to satisfy the conditions of the orders. The Commission will consider specific requests from licensees to restart a designated reactor unit on a case-by-case basis.

This decision was made following a Commission hearing on September 10, 2021. A detailed Record of Decision will be published at a later date on our website.

Read the decision at:

<https://nuclearsafety.gc.ca/eng/the-commission/pdf/SummaryDecision-September10-CMD21-H11-e.pdf>